Recombinant human albumin-interferon α2b fusion protein (Beijing Meifuyuan Biomedicine)

重组人血清白蛋白-干扰素α2b融合蛋白（北京美福源生物医药）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRecombinant human albumin-interferon α2b fusion protein (Beijing Meifuyuan Biomedicine)
Drug Alias NamerHSA-IFNα2b重组人血清白蛋白-干扰素α2b融合蛋白注射液Recombinant human serum albumin-interferon alpha fusion protein (Beijing Meifuyuan Biomedicine)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis, Viral, HumanHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Meifuyuan Biomedical Technology Co LtdTianjin Linda Biotechnology Co LtdFortunerock (China) Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTianjin Linda Biotechnology Co LtdFortunerock (China) LtdBeijing Meifuyuan Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsHepatitis, Viral, Human

Other Information

ATC CodeN/A
Related LinksN/A